Ipsen and Active Biotech discontinue tasquinimod development in prostate cancer

16 April 2015

Swedish company Active Biotech (Nasdaq Stockholm: ACTI) and French pharma firm Ipsen (Euronext Paris: IPN) are to discontinue the development of tasquinimod in prostate cancer.

The companies announced top-line results from the 10TASQ10 study, which showed that although the drug reduced the risk of radiographic cancer progression or death compared to placebo, it did not extend overall survival in patients with metastatic, castration-resistant prostate cancer who have not received chemotherapy.

The efficacy results and preliminary safety data do not support positive benefit risk balance in this population, so both companies have decided to discontinue studies in prostate cancer.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK